Professor Ragnhild Lothe og Jebsen senteret for tarmkreftforskning ved DNR
Professor Kjetil Taskèn, Norwegian Center for Molecular Medicine
Professor Kjersti Flatmark, Oslo University Hosptal, DNR
National
All HPB departments at the other University Hospitals in Norway in the ASAC-study (a randomized controlled Multicenter study for the effect of adjuvant ASA following resection of colorectal liver metastases)
International
Scandinavian network on HPB Surgery on several collaborative studies with the University Hospitals in Lund, Gothenburg, Linkøping, Stocholm, Uppsala (Sweden) and Rigshospitalet, Copenhagen (Denmark) through the IHPBA Scandinavian Chapter.
Collaboration on the Orange2+ study. PI: Ronald van Dam, Maastricht, The Netherlands
Professor Edwin participates in several international multiinstitutional projects and research groups related to MIS.
Aune D, Nordsletten M, Myklebust TÅ, Robsahm TE, Skålhegg BS, Mala T, Yaqub S, Saeed U(2025) Body mass index and risk of connective and soft tissue cancer: results from a large cohort of 1.7 million individuals in Norway BMC Cancer, 25(1), 243 DOI 10.1186/s12885-025-13637-8, PubMed 39934750
Ghadimi M, Pelzer U, Besselink MG, Siveke J, Telgmann R, Braren R, Wilmink H, Crede M, Koenig A, Koenig U, Liffers ST, Antweiler K, Uijterwijk B, Seppanen H, Nordin A, Puolakkainen P, Dajani OF, Labori KJ, Johansson M, Bratlie SO, Friede T, Jo P(2025) Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial BMC Cancer, 25(1), 208 DOI 10.1186/s12885-025-13573-7, PubMed 39915735
Rompen IF, Stoop TF, van Roessel S, van Veldhuisen E, Janssen QP, Alseidi A, Balduzzi A, Balzano G, Berrevoet F, Bonds M, Busch OR, Butturini G, Javed AA, Del Chiaro M, Conlon KC, Falconi M, Frigerio I, Fusai GK, Gagnière J, Griffin O, Hackert T, Sparrelid E, Halimi A, Labori KJ, Malleo Get al.(2025) Validation of the PANAMA-Score for Survival and Benefit of Adjuvant Therapy in Patients with Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Ann Surg(in press) DOI 10.1097/SLA.0000000000006650, PubMed 39886770